CD227抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Raji cells using CD227 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CD227 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using CD227 mouse mAb with DAB staining.    

  
  

CD227. also known as mucin 1 (MUC1), is a transmembrane glycoprotein widely studied for its role in cancer biology and immunology. It is characterized by a heavily glycosylated extracellular domain with variable numbers of tandem repeats (VNTRs), a transmembrane region, and a cytoplasmic tail involved in signaling. Normally expressed on the apical surface of epithelial cells, MUC1 functions in lubrication, cell adhesion, and immune protection. However, in malignancies such as breast, pancreatic, ovarian, and lung cancers, MUC1 undergoes aberrant overexpression and hypo-glycosylation, exposing tumor-specific epitopes that promote metastasis, immune evasion, and chemoresistance.

CD227 antibodies target specific epitopes of MUC1. particularly those within the VNTR region or altered glycoforms unique to cancer cells. These antibodies have diverse applications: diagnostic tools (e.g., immunohistochemistry for tumor detection), therapeutic agents (e.g., antibody-drug conjugates or radioimmunotherapy), and immune modulators (e.g., CAR-T cell targeting). Notably, clinical trials have explored anti-MUC1 monoclonal antibodies like PankoMab or trastuzumab emtansine (T-DM1) in cancers with MUC1 overexpression. Challenges include heterogeneity in MUC1 glycosylation patterns across tumors and potential off-target effects due to low-level expression in healthy tissues. Recent research focuses on glycoengineered antibodies or multi-epitope targeting to enhance specificity. Additionally, MUC1-based vaccines utilizing CD227 antibody-recognized epitopes are under investigation to stimulate anti-tumor immunity. Despite complexities, CD227 antibodies remain promising for precision oncology, bridging diagnostics and targeted therapies.